NCT02810119

To Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Conjunctivochalasis

A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Ocuwize LTD · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients with Moderate to Severe Conjunctivochalasis

Detailed description

Phase 2a, randomized, placebo-controlled, pilot study in up to 21 adult patients with moderate to severe CCh. Eligible patients will be randomly assigned in a 2:1 (active:placebo) ratio to one of two treatment groups, LO2A or placebo. This study with 4 visits, will consist of a screening period of up to 2 weeks and a 3-month treatment period (topical, OU, QID application of eye drops).

Conditions

• Conjunctivochalasis

Interventions

Type	Name	Description
DRUG	LO2A
DRUG	Placebo

Timeline

• Start date: 2016-11-01
• Primary completion: 2017-10-01
• Completion: 2017-10-01
• First posted: 2016-06-22
• Last updated: 2017-10-27

Locations

1 site across 1 country: Israel